NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: NASDAQ:SLS), a biopharmaceutical company specializing in cancer treatment development, announced a restructuring of its executive leadership aimed at advancing its clinical programs and optimizing resources. The company confirmed the departure of Senior Vice President, Chief Commercial Officer, Robert Francomano, and Executive Vice President, General Counsel and Corporate Secretary, Barbara Wood.
President and CEO Angelos Stergiou expressed confidence in the restructured leadership's ability to progress the company's clinical programs. Upcoming milestones include interim analysis of the Phase 3 REGAL trial of GPS in Acute Myeloid Leukemia (AML) and reporting of topline data from the Phase 2a SLS009 trial in refractory/relapsed AML this quarter, with additional data expected in the second quarter. SELLAS also anticipates topline results from the Phase 1b/2 study of SLS009 in Peripheral T-Cell Lymphoma (PTCL) in the second quarter.
Dr. Stergiou acknowledged the contributions of Francomano and Wood to SELLAS's development and wished them well in future endeavors. He highlighted the company's progress in commercial market access, pricing strategies, and reimbursement initiatives, which position SELLAS for continued success in the REGAL trial of GPS and its potential as a new AML treatment.
SELLAS has engaged a commercial consultant with a strong track record, including the launch of Venetoclax, to maintain operational excellence. Stacy Yeung, promoted to Vice President, Associate General Counsel, and Head of Compliance, will lead the company's legal and compliance functions with her 20 years of experience.
SELLAS's lead product candidate, GPS, targets the WT1 protein present in various tumor types and has potential as a monotherapy or in combination with other therapies for a wide range of hematologic malignancies and solid tumors. The company is also developing SLS009, a selective CDK9 inhibitor, for therapeutic and diagnostic uses outside of Greater China.
This announcement is based on a press release statement from SELLAS Life Sciences Group, Inc. The forward-looking statements contained in the press release involve risks and uncertainties that could cause actual results to differ materially from those anticipated.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.